Beijing Tide Pharmaceuticals Submits NDA for TRD303, a Novel 72-Hour Long-Acting Postoperative Analgesic
Fosun Wanbang Pharma Group
Drug Developer
GENRIX BIO
Developer of Novel Monoclonal Antibody Drugs
CSPC
Innovative Drug Research and Development, Manufacturer
Guangzhou Baiyunshan Pharmaceutical Holdings Company
Integrated Service Provider for Pharmaceuticals and Medical Devices
Note: The weekly data cutoff date is set to Friday, with Saturday and Sunday data carried over to the following week.
Several notices were issued this week, starting on June 30, includingFosun Wanbang Pharma Group'sFinerenone Tablets,GENRIX BIO Voluntarily WithdrawsClass 1 New DrugTelitacicept Injection: Zhejiang Hengyan Pharmaceutical Received Two Notification Letters Within One DayAcetylcysteine Injection andDydrogesterone Tablets, all contract manufactured by Zhejiang Saimo.
On July 1, multiple approval documents were issued again, including Hybio’s chemically synthesized version of liraglutide.Adamerck Pharma’s Class 1 new drug, Sugammadex Sodium Injection, has been approved. This drug is the only one of its kind in China and one of only two globally as a targeted neuromuscular blocking agent reversal agent. This isDevelopment based on sugammadex sodium.
CSPC’s Iron Sucrose Injection Becomes the First to Pass Quality Consistency Evaluation, Yet on the Same Day, Yangtze River’sMeloxicam Injection (III) Approved, Ending CSPC’s Exclusive Status.
As is well known, pain management has been moving away from opioid abuse. This week, Beijing Tide Pharmaceutical's improved new drugA marketing application has been submitted for the extended-release ropivacaine hydrochloride solution, which is also indicated for postoperative analgesia.Meloxicam injection provides analgesia for only 22–24 hours, whereasRopivacaine Hydrochloride Sustained-Release Solution Provides Analgesia for 72 Hours: A Super Competitor Has Arrived.
Additionally, this week,Merck Imported Innovative DrugsThe first and only drug for the treatment of desmoid tumors,Marketing Application for Nilrostostat Hydrobromide Tablets AcceptedHuahai Pharmaceutical has produced Imrecoxib Tablets, an exclusive product of Hengrui Medicine.Jiangsu Xuantai Pharmaceutical has submitted a marketing application for the popular insomnia drug lemborexant tablets, while Guangzhou Baiyunshan Pharmaceutical Holdings Company has officially entered the sildenafil oral dissolving film market under its “Jinge” brand.
